Metabolic dysfunction‐associated steatotic liver disease (SLD) and alcohol‐associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10‐year follow‐up period

Documenti analoghi

• Deciphering metabolic dysfunction‐associated steatotic liver disease: insights from predictive modeling and clustering analysis
  di: Kazuma Mori, et al.
  Pubblicazione: (2024)
• Association of liver fibrosis progression with non–liver‐related mortality in metabolic dysfunction‐associated steatotic liver disease
  di: Toshifumi Tada, et al.
  Pubblicazione: (2025)
• Therapeutic management of metabolic dysfunction associated steatotic liver disease
  di: Jing Zeng, et al.
  Pubblicazione: (2024)
• Low thyroid function is associated with metabolic dysfunction‐associated steatotic liver disease
  di: Shuo Wang, et al.
  Pubblicazione: (2024)
• Exploring a Subpopulation of MASLD Associated With New Onset of CKD Using Supervised Clustering Techniques
  di: Itaru Hosaka, et al.
  Pubblicazione: (2026)